Serological Biomarker Discovery for IBD

Serological testing is a non-invasive test for inflammatory bowel disease (IBD) and for the differentiation between ulcerative colitis (UC) and Crohn's disease (CD). There have been a few biomarkers found in the past decade, mostly antibodies produced against common intestinal bacteria in susceptible individuals. It is unknown what these antibodies are for, but they're characteristic of patients with IBD and can suggest a pathogenic response to bacterial antigens. More targeted and sensitive serological biomarkers are required and future research to evaluate the value of existing and newly discovered biomarkers for IBD is needed.

Fig. 1. Overall strategy for the identification of novel serological biomarkers for inflammatory bowel disease. Fig. 1. Overall strategy for the identification of novel serological biomarkers for IBD using E. coli whole proteome chip. (Chen et al., 2009)

Serological Biomarker Discovery Services

Ace Therapeutics is a trusted provider of biomarker discovery services for clients to screen and discover new serological biomarkers for IBD. We built a platform of leading proteomics technologies and support post-project to help clients discover biomarkers that can be used to monitor IBD treatment response.

Technologies We Use

Our scientists collaborate with you to determine your research goals and plan a project to help you achieve those goals fast and effectively, from sample size to technology platforms for discovery and validation.

Next Generation Sequencing (NGS) Platform	We can sequence gut microbiota and host genome DNA to link certain genetic markers and microbial communities to serologic responses to find IBD biomarkers.
Enzyme-linked Immunosorbent Assay (ELISA)	It detects and measures specific antibodies in serum samples. We identify antibodies that may be associated with disease activity or type of IBD by using known antigens.
Mass Spectrometry	Various mass spectrometry techniques are employed to analyze proteins present in serum. They provide insights into the immune response associated with IBD due to their high sensitivity in detecting low-abundance biomarkers. We utilize this technology to assist our clients in identifying new biomarkers linked to the development of IBD.
Protein Chip (Array)	We use protein arrays to screen circulating disease-specific antibodies, which is a robust, effective, and high throughput approach for discovery of novel biomarkers of IBD.

Serological Biomarkers You May Be Interested In

Our knowledge and expertise with biomarker discovery services allow us to assist with the discovery of IBD relevant serological biomarkers, while measuring and interpreting their changes within animal models, relating them to the drug development program.

Types of Serological Biomarkers	Samples
Autoantibodies	Perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) Antibodies against exocrine pancreas (PABs) Antibodies to goblet cells (GAB) Anti-granulocyte macrophage colony-stimulating factor (anti-GM-CSF) antibodies Anti-chitinase-3-like protein 1 (anti-CHI3L1)
Antibodies to microbial antigens	Anti-Saccharomyces cerevisiae antibodies (ASCA) Anti-chitobioside carbohydrate antibodies (ACCA) Anti-laminaribioside carbohydrate antibodies (ALCA) Anti-mannobioside carbohydrate antibodes (AMCA) Anti-laminarin antibodies (Anti-L) Anti-chitin antibodies (Anti-C) Antibody to outer membrane porin C (Anti-OmpC) Antibody to pseudomonas fluorescens - associated sequence I2 (Anti-I2) Antibody to bacterial flagellin (Anti-Cbir1)

Ace Therapeutics provides comprehensive support to clients through specialized serological biomarker discovery services. Our specialists understand the complex process of selecting, validating, and applying serological biomarkers of IBD. From IBD drug discovery to serum sample analysis, we enable informed decision-making and reduce risk at critical stages of your program. If you are interested in our services, please do not hesitate to contact us.

Reference

Chen, C. S., et al. (2009). Identification of novel serological biomarkers for inflammatory bowel disease using Escherichia coli proteome chip. Molecular & Cellular Proteomics, 8(8), 1765-1776.

! For research use only, not intended for any clinical use.